What is the appropriate post‑operative treatment and surveillance strategy for a patient with stage IB hepatocellular carcinoma (solitary tumor 2–5 cm) after curative hepatectomy?

Post-Hepatectomy Management for Stage IB Hepatocellular Carcinoma

No adjuvant therapy is recommended after curative hepatectomy for stage IB HCC, but adjuvant atezolizumab plus bevacizumab should be strongly considered for high-risk patients based on the most recent evidence. 1

Adjuvant Therapy Recommendations

Standard Approach

The ESMO-ESDO guidelines explicitly state that neo-adjuvant or adjuvant therapies are not recommended to improve outcomes after resection 1. This recommendation is based on Level II evidence showing no clear benefit from traditional adjuvant protocols including immunotherapy, retinoids, or chemoembolization.

Emerging Exception for High-Risk Disease

However, the 2024 British Society of Gastroenterology guidelines now recommend adjuvant atezolizumab plus bevacizumab for improving recurrence-free survival in appropriately selected patients 2. This represents the most recent high-quality guideline evidence and reflects results from the IMbrave050 trial 3, which demonstrated improved recurrence-free survival in patients with high-risk HCC after resection or ablation. The 2025 EASL guidelines also reference this trial 3.

Key consideration: While this improves recurrence-free survival, longer-term follow-up data on overall survival are still needed 2. The decision to use adjuvant immunotherapy should be based on:

• Pathological risk factors (microvascular invasion, poor differentiation)
• Tumor size within the 2-5 cm range (stage IB)
• Patient performance status and liver function
• Absence of contraindications to immunotherapy

Surveillance Strategy

Intensive Early Surveillance (First 2 Years)

Perform multiphase CT or MRI every 3 months for the first 2 years post-hepatectomy 4, 5. This intensive approach is critical because:

• Nearly half of all recurrences occur within 9 months of hepatectomy 6
• Recurrence is 6.5 times more likely in the first year than the second year 4
• Early recurrence (within 9 months) has significantly worse median survival (36.2 vs 65.7 months) 6
• 80% of recurrences occur in the liver alone 6

Do not use ultrasound for surveillance in the first 2 years due to low sensitivity for detecting early recurrence 4, 5.

Imaging Protocol Specifics

Use three-phase or four-phase CT/MRI including:

• Arterial phase
• Portal venous phase
• Delayed phase
• Non-contrast phase (particularly important if future liver-directed therapy may be needed) 4, 5

MRI is often preferred over CT for long-term surveillance to minimize cumulative radiation exposure 5.

Extended Surveillance (After 2 Years)

Transition to imaging every 6-12 months after completing 2 years of intensive surveillance 4, 5. At this point, ultrasound every 6 months may be acceptable as recurrence risk decreases 4.

Response Assessment

Use modified RECIST criteria on dynamic CT or MRI to evaluate any suspicious lesions 1.

Management of Detected Recurrence

For Limited Intrahepatic Recurrence (≤2 tumors, each ≤3 cm)

Repeat hepatectomy or ablation therapy are equally effective and superior to TACE 7. Both achieve significantly better survival than transarterial chemoembolization in this setting.

For More Extensive Recurrence (≥3 tumors or any tumor ≥3 cm)

Treatment options become more limited with poorer outcomes 7. TACE or systemic therapy should be considered based on liver function and tumor burden.

Common Pitfalls to Avoid

1. Underestimating early recurrence risk: The first 9 months are critical—do not delay or skip surveillance imaging during this window
2. Using ultrasound too early: Ultrasound has inadequate sensitivity for post-resection surveillance in the first 2 years
3. Ignoring high-risk pathological features: Microvascular invasion, tumor size, and differentiation should guide consideration of adjuvant immunotherapy
4. Inconsistent imaging protocols: Ensure multiphase technique is used consistently to detect arterial enhancement and washout patterns characteristic of HCC recurrence

Additional Considerations

Antiviral therapy should be continued or initiated if the patient has chronic hepatitis B or C, as this may reduce recurrence risk even after curative resection 1.

Salvage liver transplantation may be considered for select patients who develop recurrence within transplant criteria, though this requires early detection through rigorous surveillance 3.